TILT Biotherapeutics raises $10M to push ahead on cancer immunotherapies
TILT Biotherapeutics (TILT), a clinical-stage Finnish biotech company developing cancer immunotherapies, has completed the first…
June 15, 2022 - 2 minutes
CAR-T Cell Therapy: Revolutionizing Oncology One Step at a Time
The idea that our immune system can be rewired to fight cancer has resulted in huge expectations and an influx of investments into the immuno-oncology field. Following the market success of immune checkpoint inhibitors, more and more attention is turning to CAR-T cell therapy, with the first CAR-T therapy, Novartis’ Kymriah, approved in 2017.
With five CAR-T therapies on the global market already and over hundreds of clinical trials currently running, the field is now booming. Read on to keep up-to-date with the evolving CAR-T cell therapy market and ongoing research.
Show More
Editor's Picks for CAR-T
- A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology
- Infographic: What is CAR-T Cell Therapy & How Does it Fight Cancer?
- From Big Pharma to Startup CEO: Lessons from Kymriah Developer Gaurav Shah
- Gene-Edited T Cell Therapy Players Battle Safety Doubts
- How European Startups Have Advanced Cancer T-Cell Therapy in 2020
A Guide to Current Therapies in Immuno-Oncology
From a rich history to a growing number of therapies, the immuno-oncology landscape has changed rapidly over the last decade. In this report, we look into its past, discuss present therapeutic approaches, and provide an outlook into its future.
Go to ReportLatest CAR-T Articles
Japan’s five hottest biotech companies in healthcare
While historically lacking in foreign investments, Japan’s biotech scene is thriving with global investors showing…
June 15, 2022 - 6 minutes
Sponsored
by Takara Bio
Combination Therapies: Opportunities for Improved CAR-T Cell Therapy?
Chimeric antigen receptor (CAR) cell therapy offers hope where other cancer therapies have failed. However,…
March 10, 2022 - 6 minutes
Gene-Edited T Cell Therapy Players Battle Safety Doubts
Confidence in gene-edited T cell therapies from donor cells has faltered as Allogene Therapeutics paused…
October 22, 2021 - 5 minutes
A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology
CAR-T therapy has been hailed as a cure for cancer, but what really is this…
October 11, 2021 - 10 minutes
Microbiome Medicines Could Power Up CAR-T Cell Therapies
The microbiome could pave new cancer immunotherapy inroads for European biotechs, bolstered by preclinical findings…
July 28, 2021 - 5 minutes
Scotland’s Top 10 Biotech Companies to Watch Out For
Scotland has a thriving life sciences ecosystem with strengths in oncology, genetic engineering, and industrial…
June 30, 2021 - 11 minutes
Navigating the Immunotherapy Maze
Today, the global immunotherapy drugs market is valued at €139B ($163B) and is estimated to…
November 11, 2020 - 2 minutes
Do Natural Killer Cells Hold the Key to Treating Blood Cancers?
Novel immunotherapies, like T cell therapy, may have shown recent successes but they also come…
October 28, 2020 - 7 minutes
From Big Pharma to Startup CEO: Lessons from Kymriah Developer Gaurav Shah
Novartis’ Kymriah, one of the first CAR T-cell therapies to be approved to treat blood…
September 28, 2020 - 9 minutes
T-Cell Therapy Firm Wins Massive €93M Series A to Treat Solid Tumors
The Dutch startup Neogene Therapeutics has become the second T-cell therapy developer to raise a…
September 14, 2020 - 3 minutes
How European Startups Have Advanced Cancer T-Cell Therapy in 2020
With the help of a huge €66M Series A round last week, the German startup…
August 11, 2020 - 8 minutes
